Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2013/724360 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832557124863918080 |
|---|---|
| author | Ahmad Hamad Zeyad Sahli Maya El Sabban Maha Mouteirik Rihab Nasr |
| author_facet | Ahmad Hamad Zeyad Sahli Maya El Sabban Maha Mouteirik Rihab Nasr |
| author_sort | Ahmad Hamad |
| collection | DOAJ |
| description | Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient must manage for life. Although tyrosine kinase inhibitors (TKI) therapy has completely transformed the prognosis of CML, it has made the therapeutic management more complex. The interruption of TKI treatment results in early disease progression because it does not eliminate quiescent CML stem cells which remain a potential reservoir for disease relapse. This highlights the need to develop new therapeutic strategies for CML to achieve a permanent cure, and to allow TKI interruption. This review summarizes recent research done on alternative targeted therapies with a particular focus on some important signaling pathways (such as Alox5, Hedgehog, Wnt/b-catenin, autophagy, and PML) that have the potential to target CML stem cells and potentially provide cure for CML. |
| format | Article |
| id | doaj-art-bb3712d3cc474e75bf3f900b50c7a74e |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-bb3712d3cc474e75bf3f900b50c7a74e2025-02-03T05:43:34ZengWileyStem Cells International1687-966X1687-96782013-01-01201310.1155/2013/724360724360Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem CellsAhmad Hamad0Zeyad Sahli1Maya El Sabban2Maha Mouteirik3Rihab Nasr4Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, LebanonDepartment of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, LebanonDepartment of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, LebanonDepartment of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, LebanonDepartment of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, LebanonChronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient must manage for life. Although tyrosine kinase inhibitors (TKI) therapy has completely transformed the prognosis of CML, it has made the therapeutic management more complex. The interruption of TKI treatment results in early disease progression because it does not eliminate quiescent CML stem cells which remain a potential reservoir for disease relapse. This highlights the need to develop new therapeutic strategies for CML to achieve a permanent cure, and to allow TKI interruption. This review summarizes recent research done on alternative targeted therapies with a particular focus on some important signaling pathways (such as Alox5, Hedgehog, Wnt/b-catenin, autophagy, and PML) that have the potential to target CML stem cells and potentially provide cure for CML.http://dx.doi.org/10.1155/2013/724360 |
| spellingShingle | Ahmad Hamad Zeyad Sahli Maya El Sabban Maha Mouteirik Rihab Nasr Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells Stem Cells International |
| title | Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells |
| title_full | Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells |
| title_fullStr | Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells |
| title_full_unstemmed | Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells |
| title_short | Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells |
| title_sort | emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells |
| url | http://dx.doi.org/10.1155/2013/724360 |
| work_keys_str_mv | AT ahmadhamad emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells AT zeyadsahli emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells AT mayaelsabban emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells AT mahamouteirik emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells AT rihabnasr emergingtherapeuticstrategiesfortargetingchronicmyeloidleukemiastemcells |